Jin - Figure 43 - ACOG Response to New Guidelines
In a response to the new ACS/ASCCP/ASSCP and USPSTF Guidelines, ACOG endorsed co-testing in women
ages 30-65. They reiterated the higher sensitivity and negative predictive value conferred by co-testing allowing
a potential precancerous lesion to be identified sooner.
Accordingly, women need to hear the message that with co-testing less is truly more. The bottom line is that
cervical cancer screening must reduce cervical cancer, and there is high quality evidence that co-testing does
just that.
